Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open-label Phase 3 Trial Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

NCT02633189 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT02633189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02633189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open-label Phase 3 Trial Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer
Lead sponsor
National Cancer Institute, Naples
Phase
Phase 3
Overall status
Unknown status
Start date
April 30, 2016
Completion date
July 31, 2024
Enrollment
200 (estimated)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer